Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
Karin Hardt, An Vandebosch, Jerald Sadoff, Mathieu Le Gars et autres
be, nl, gb, de (code pays fourni par la source)
90 citations
The Lancet Infectious Diseases